

PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/602,394		
		Filing Date	June 23, 2003		
		First Named Inventor	Carrie Haskell-Luevano		
		Group Art Unit	1646		
		Examiner Name	Not yet assigned		
Sheet	1	of	1	Attorney Docket Number	UF-375

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
8	R1	Han, G., J.M. quillan, K. Carlson, W. Sadee, V.J. Hruby (February 27, 2003) "Design of Novel Chi8meric Melanotropin-Deltrophin Analogues. Discovery of the First Potent Human Melanocortin 1 Receptor Antagonist" <i>J. Med. Chem.</i> 46:810-819.	
8	R2	Joseph, Christine G., Andrzej Wilczynski, Jerry R. Holder, Zhimin Xiang, Rayna M. Bauzo, Joseph W. Scott, Carrie Haskell-Luevano (December 2003) "Chimeric NDP-MSH and MTII melanocortin peptides with agouti-related protein (AGRP) Arg-Phe-Phe amino acids possess agonist melanocortin receptor activity" <i>Peptides</i> 24(12):1899-1908.	
8	R3	Szardenings, Michael <i>et al.</i> (October 31, 1997) "Phage Display Selection on Whole Cells Yields a Peptide Specific for Melanocortin Receptor 1" <i>Journal of Biological Chemistry</i> 272(44):27943-27948.	
8	R4	Wilczynski, Andrzej, Xiang S. Wang, Christine G. Joseph <i>et al.</i> (April 22, 2004) "Identification of Putative Agouti-Related Protein (87-132)-Melanocortin-4 Receptor Interactions by Homology Molecular Modeling and Validation Using Chimeric Peptide Ligands" <i>J. Med. Chem.</i> 47(9):2194-2207.	
	R5		
	R6		
	R7		
	R8		
	R9		


Examiner Signature		Date Considered	2/27/06
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/602,394
Filing Date	June 23, 2003
First Named Inventor	Carrie Haskell-Luevano
Art Unit	(not yet assigned)
Examiner Name	(not yet assigned)
Attorney Docket Number	UF-375

Sheet

1

of

3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* <sup>2</sup> (if known)			
<i>B</i> <i>1</i>	U1	US- 6,127,381	10-03-2000	Basu <i>et al.</i>	All
	U2	US- 6,451,783      B1	09-17-2002	Hadcock <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)					
8	F1	WO	01/74844 A2		10-11-2001	F. Hoffmann-La Roche Ag	All	
8	F2	WO	02/18437 A2		03-07-2002	F. Hoffmann-La Roche Ag	All	
8	F3	WO	03/006620 A2		01-23-2003	Palatin Technologies, Inc.	All	
8	F4	WO	99/21571 A1		05-08-1999	Trega Biosciences, Inc.	All	
8	F5	WO	99/54358 A1		10-28-1999	Quadrant Holdings Cambridge Limited	All	
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner  
SignatureDate  
Considered

epr22/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/602,394	
			Filing Date	June 23, 2003	
			First Named Inventor	Carrie Haskell-Luevano	
			Group Art Unit	(not yet assigned)	
			Examiner Name	(not yet assigned)	
Sheet	2	of	3	Attorney Docket Number	UF-375

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
8	R1	BOLIN, K.A. <i>et al.</i> "NMR Structure of a Minimized Human Agouti Related Protein Prepared by Total Chemical Synthesis" <i>FEBS Letters</i> , 1999, pp. 125-131, Vol. 451.	
8	R2	CASTRUCCI, A.M.L. <i>et al.</i> " $\alpha$ -Melanotropin: The Minimal Active Sequence in the Lizard Skin Bioassay" <i>General and Comparative Endocrinology</i> , 1989, pp. 157-163, Vol. 73.	
8	R3	HRUBY, V.J. <i>et al.</i> " $\alpha$ -Melanotropin: The Minimal Active Sequence in the Frog Skin Bioassay" <i>J. Med. Chem.</i> , 1987, pp. 2126-2130, Vol. 30.	
8	R4	HOLDER, J. R. <i>et al.</i> "Structure-Activity Relationships of the Melanocortin Tetrapeptide Ac-His-DPhe-Arg-Trp-NH <sub>2</sub> at the Mouse Melanocortin Receptors. 1. Modifications at the His Position" <i>J. Med. Chem.</i> , 2002, pp. 2801-2810, Vol. 45.	
8	R5	HOLDER, J. R. <i>et al.</i> "Structure-Activity Relationships of the Melanocortin Tetrapeptide Ac-His-DPhe-Arg-Trp-NH <sub>2</sub> at the Mouse Melanocortin Receptors: Part 2 Modifications at the Phe Position" <i>J. Med. Chem.</i> , 2002, pp. 3073-3081, Vol. 45.	
8	R6	JACKSON, P. J. <i>et al.</i> "Design, Pharmacology, and NMR Structure of a Minimized Cystine Knot with Agouti-Related Protein Activity" <i>Biochemistry</i> , 2002, pp.7565-7572, Vol. 41. No. 24.	
8	R7	KAVARANA, M. J. <i>et al.</i> "Novel Cyclic Templates of $\alpha$ -MSH Give Highly Selective and Potent Antagonists/Agonists for Human Melanocortin-3/4 Receptors" <i>J. Med. Chem.</i> , 2002, pp. 2644-2650, Vol. 45.	
8	R8	KIEFER, L. L. <i>et al.</i> "Melanocortin Receptor Binding Determinants in the Agouti Protein" <i>Biochemistry</i> , 1998, pp. 991-997, Vol. 37.	
8	R9	KIEFER, L. L. <i>et al.</i> "Mutations in the Carboxyl Terminus of the Agouti Protein Decrease Agouti Inhibition of Ligand Binding to the Melanocortin Receptors" <i>Biochemistry</i> , 1997, pp. 2084-2090, Vol. 36.	
8	R10	KIM <i>et al.</i> , "Hypothalamic Localization of the Feeding Effect of Agouti-Related Peptide and $\alpha$ -Melanocyte-Stimulating Hormone," <i>Diabetes</i> , February 2000, pp. 177-182, Vol. 49.	
8	R11	HASKELL-LUEVANO, C. <i>et al.</i> "Characterization of Melanocortin NDP-MSH Agonist Fragments at the Mouse Central and Peripheral Melanocortin Receptors" <i>J. Med. Chem.</i> , 2001, pp. 2247-2252, Vol. 44.	
8	R12	HASKELL-LUEVANO, C. <i>et al.</i> "The Agouti-Related Protein Decapeptide (Yc[CRFFNAFC]Y) Possesses Agonist Activity at the Murine Melanocortin-1 Receptor" <i>Peptides</i> , 2000, pp. 683-689, Vol. 21.	
8	R13	HASKELL-LUEVANO, C. <i>et al.</i> "Structure Activity Studies of the Melanocortin-4 Receptor by <i>in Vitro</i> Mutagenesis: Identification of Agouti-Related Protein (AGRP), Melanocortin Agonist and Synthetic Peptide Antagonist Interaction Determinants" <i>Biochemistry</i> , 2001, pp. 6164-6179, Vol. 40.	


Examiner Signature		Date Considered	2/27/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Applicati n Number	10/602,394
Filing Date	June 23, 2003
First Named Inventor	Carrie Haskell-Luevano
Group Art Unit	(not yet assigned)
Examiner Name	(not yet assigned)
Attorney Docket Number	UF-375

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
8	R14	McNulty, J. C. <i>et al.</i> "High-Resolution NMR Structure of the Chemically-Synthesized Melanocortin Receptor Binding Domain AGRP(87-132) of the Agouti-Related Protein" <i>Biochemistry</i> , 2001, pp. 15520-15527. Vol. 40.	
8	R15	AL-OBEIDI, F. <i>et al.</i> "Potent and Prolonged Acting Cyclic Lactam Analogues of $\alpha$ -Melanotropin: Design Based on Molecular Dynamics" <i>J. Med. Chem.</i> 1989, pp. 2555-2561, Vol. 32.	
8	R16	OOSTEROM, J. <i>et al.</i> "Common Requirements for Melanocortin-4 Receptor Selectivity of Structurally Unrelated Melanocortin Agonist and Endogenous Antagonist, Agouti Protein" <i>The Journal of Biological Chemistry</i> , January 12, 2001, pp. 931-936, Vol. 276, No. 2.	
8	R17	PERRY, W. L. <i>et al.</i> "A Transgenic Mouse Assay for Agouti Protein Activity" <i>Genetics</i> , May 1995, pp. 267-274, Vol. 140.	
8	R18	PERRY, W. L. <i>et al.</i> "Coupled Site-Directed Mutagenesis/Transgenesis Identifies Important Functional Domains of the Mouse Agouti Protein" <i>Genetics</i> , September 1996, pp. 255-264, Vol. 144.	
8	R19	QUILLAN, J. M. <i>et al.</i> "A Synthetic Human Agouti-Related Protein-(83-132)-NH <sub>2</sub> Fragment is a Potent Inhibitor of Melanocortin Receptor Function" <i>FEBS Letters</i> , 1998, pp. 59-62, Vol. 428.	
8	R20	SAWYER, T. K. <i>et al.</i> "4- Norleucine, 7-D-Phenylalanine- $\alpha$ -Melanocyte-Stimulating Hormone: A Highly Potent $\alpha$ -Melanotropin with Ultralong Biological Activity" <i>Biochemistry</i> , October 1980, pp. 5754-5758, Vol. 77, No. 10.	
8	R21	TOTA, M. R. <i>et al.</i> "Molecular Interaction of Agouti Protein and Agouti-Related Protein with Human Melanocortin Receptors" <i>Biochemistry</i> , 1999, pp. 897-904, Vol. 38.	
8	R22	WILLARD, D. H. <i>et al.</i> "Agouti Structure and Function: Characterization of a Potent $\alpha$ -Melanocyte Stimulating Hormone Receptor Antagonist" <i>Biochemistry</i> , 1995, pp. 12341-12346, Vol. 34.	
8	R23	YANG, Y-K. <i>et al.</i> "Functional Properties of an Agouti Signaling Protein Variant and Characteristics of its Cognate Radioligand" <i>Am. J. Physiol Regulatory Integrative Comp. Physiol.</i> , 2001, pp. R1877-R1886, Vol. 281.	
8	R23	YANG, Y-K. <i>et al.</i> "Molecular Determinants of Ligand Binding to the Human Melanocortin-4 Receptor" <i>Biochemistry</i> , 2000, pp. 14900-14911, Vol. 39.	
8	R25	YANG, Y-K. <i>et al.</i> "Characterization of Agouti-Related Protein Binding to Melanocortin Receptors" <i>Molecular Endocrinology</i> , 1999, pp. 148-155.	
	R26		

Examiner  
SignatureDate  
Considered

2/27/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.